Compare Bank of America Corp (BAC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Incyte Corporation — how do they compare? Bank of America Corp trades at $63.99 (market cap $447.54B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Bank of America Corp is far larger — about 18.2× Incyte Corporation's market cap, and Bank of America Corp pays a 2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BAC | INCY | |
|---|---|---|
Market Cap | $447.54B | $24.54B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $129.93 |
52-Week Low | $46.72 | $81.61 |
Dividend Yield | 2% | — |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $63.86, up 1.09% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and revenue growth to $113.10B in 2025. Analyst consensus is strongly positive, with a $67.36 price target and 35 buy ratings. Recent news highlights strategic partnerships and hiring initiatives, reinforcing growth prospects.
BAC presents a favorable investment opportunity driven by earnings beats, robust deposit franchise, and potential capital returns post-stress tests. Risks include interest rate sensitivity and macroeconomic volatility. The stock's current valuation at a P/E of 14.78 offers room for upside relative to historical averages, supported by institutional bullishness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
